[
  {
    "cohort_id": "FDA-AEMS-2023-Q3-GLP1-01",
    "product_name": "Adlyxin",
    "active_ingredient": "lixisenatide",
    "aspiration_fda_outcome": "Label updated October–November 2024",
    "alopecia_fda_outcome": "Alopecia added December 2024–May 2025",
    "bowel_exact_phrase_present": "True",
    "bowel_label_result": "Exact phrase present",
    "si_b_2026_action": "Not part of 2026 removal request",
    "current_label_source_type": "FDA label",
    "current_label_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/208471s012lbl.pdf",
    "si_b_source_url": "",
    "cohort_definition_url": "https://www.fda.gov/drugs/fda-adverse-event-monitoring-system-aems/july-september-2023-potential-signals-serious-risksnew-safety-information-identified-fda-adverse",
    "bowel_signal_url": "https://www.fda.gov/drugs/fda-adverse-event-monitoring-system-aems/april-june-2025-new-safety-information-or-potential-signals-serious-risks-identified-fda-adverse",
    "verified_date": "2026-08-01",
    "dataset_version\r": "1.0\r"
  },
  {
    "cohort_id": "FDA-AEMS-2023-Q3-GLP1-02",
    "product_name": "Byetta",
    "active_ingredient": "exenatide",
    "aspiration_fda_outcome": "Label updated October–November 2024",
    "alopecia_fda_outcome": "Existing labeling adequate; no further action at that time",
    "bowel_exact_phrase_present": "False",
    "bowel_label_result": "Exact phrase not found; ileus listed",
    "si_b_2026_action": "Not part of 2026 removal request",
    "current_label_source_type": "DailyMed label",
    "current_label_url": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=53d03c03-ebf7-418d-88a8-533eabd2ee4f",
    "si_b_source_url": "",
    "cohort_definition_url": "https://www.fda.gov/drugs/fda-adverse-event-monitoring-system-aems/july-september-2023-potential-signals-serious-risksnew-safety-information-identified-fda-adverse",
    "bowel_signal_url": "https://www.fda.gov/drugs/fda-adverse-event-monitoring-system-aems/april-june-2025-new-safety-information-or-potential-signals-serious-risks-identified-fda-adverse",
    "verified_date": "2026-08-01",
    "dataset_version\r": "1.0\r"
  },
  {
    "cohort_id": "FDA-AEMS-2023-Q3-GLP1-03",
    "product_name": "Bydureon",
    "active_ingredient": "exenatide extended-release",
    "aspiration_fda_outcome": "Label updated October–November 2024",
    "alopecia_fda_outcome": "Existing labeling adequate; no further action at that time",
    "bowel_exact_phrase_present": "False",
    "bowel_label_result": "Exact phrase not found; ileus listed",
    "si_b_2026_action": "Not part of 2026 removal request",
    "current_label_source_type": "FDA label",
    "current_label_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/022200s036lbl.pdf",
    "si_b_source_url": "",
    "cohort_definition_url": "https://www.fda.gov/drugs/fda-adverse-event-monitoring-system-aems/july-september-2023-potential-signals-serious-risksnew-safety-information-identified-fda-adverse",
    "bowel_signal_url": "https://www.fda.gov/drugs/fda-adverse-event-monitoring-system-aems/april-june-2025-new-safety-information-or-potential-signals-serious-risks-identified-fda-adverse",
    "verified_date": "2026-08-01",
    "dataset_version\r": "1.0\r"
  },
  {
    "cohort_id": "FDA-AEMS-2023-Q3-GLP1-04",
    "product_name": "Bydureon BCise",
    "active_ingredient": "exenatide extended-release",
    "aspiration_fda_outcome": "Label updated October–November 2024",
    "alopecia_fda_outcome": "Existing labeling adequate; no further action at that time",
    "bowel_exact_phrase_present": "False",
    "bowel_label_result": "Exact phrase not found; ileus listed",
    "si_b_2026_action": "Not part of 2026 removal request",
    "current_label_source_type": "DailyMed label",
    "current_label_url": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2d18cfc4-e0de-4814-a712-c1b7c504bff5",
    "si_b_source_url": "",
    "cohort_definition_url": "https://www.fda.gov/drugs/fda-adverse-event-monitoring-system-aems/july-september-2023-potential-signals-serious-risksnew-safety-information-identified-fda-adverse",
    "bowel_signal_url": "https://www.fda.gov/drugs/fda-adverse-event-monitoring-system-aems/april-june-2025-new-safety-information-or-potential-signals-serious-risks-identified-fda-adverse",
    "verified_date": "2026-08-01",
    "dataset_version\r": "1.0\r"
  },
  {
    "cohort_id": "FDA-AEMS-2023-Q3-GLP1-05",
    "product_name": "Mounjaro",
    "active_ingredient": "tirzepatide",
    "aspiration_fda_outcome": "Label updated October–November 2024",
    "alopecia_fda_outcome": "Alopecia added December 2024–May 2025",
    "bowel_exact_phrase_present": "True",
    "bowel_label_result": "Exact phrase present",
    "si_b_2026_action": "Not part of 2026 removal request",
    "current_label_source_type": "DailyMed label",
    "current_label_url": "https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=f4edc99a-ecdb-4a68-bcb4-69fbba2190e8&type=display",
    "si_b_source_url": "",
    "cohort_definition_url": "https://www.fda.gov/drugs/fda-adverse-event-monitoring-system-aems/july-september-2023-potential-signals-serious-risksnew-safety-information-identified-fda-adverse",
    "bowel_signal_url": "https://www.fda.gov/drugs/fda-adverse-event-monitoring-system-aems/april-june-2025-new-safety-information-or-potential-signals-serious-risks-identified-fda-adverse",
    "verified_date": "2026-08-01",
    "dataset_version\r": "1.0\r"
  },
  {
    "cohort_id": "FDA-AEMS-2023-Q3-GLP1-06",
    "product_name": "Ozempic",
    "active_ingredient": "semaglutide",
    "aspiration_fda_outcome": "Label updated October–November 2024",
    "alopecia_fda_outcome": "Alopecia added December 2024–May 2025",
    "bowel_exact_phrase_present": "True",
    "bowel_label_result": "Exact phrase present",
    "si_b_2026_action": "Not part of 2026 removal request",
    "current_label_source_type": "DailyMed label",
    "current_label_url": "https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=42bdd912-2393-44c4-b7e0-47672ca28991&type=display",
    "si_b_source_url": "",
    "cohort_definition_url": "https://www.fda.gov/drugs/fda-adverse-event-monitoring-system-aems/july-september-2023-potential-signals-serious-risksnew-safety-information-identified-fda-adverse",
    "bowel_signal_url": "https://www.fda.gov/drugs/fda-adverse-event-monitoring-system-aems/april-june-2025-new-safety-information-or-potential-signals-serious-risks-identified-fda-adverse",
    "verified_date": "2026-08-01",
    "dataset_version\r": "1.0\r"
  },
  {
    "cohort_id": "FDA-AEMS-2023-Q3-GLP1-07",
    "product_name": "Rybelsus",
    "active_ingredient": "semaglutide",
    "aspiration_fda_outcome": "Label updated October–November 2024",
    "alopecia_fda_outcome": "Alopecia added December 2024–May 2025",
    "bowel_exact_phrase_present": "True",
    "bowel_label_result": "Exact phrase present",
    "si_b_2026_action": "Not part of 2026 removal request",
    "current_label_source_type": "DailyMed label",
    "current_label_url": "https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=27f15fac-7d98-4114-a2ec-92494a91da98",
    "si_b_source_url": "",
    "cohort_definition_url": "https://www.fda.gov/drugs/fda-adverse-event-monitoring-system-aems/july-september-2023-potential-signals-serious-risksnew-safety-information-identified-fda-adverse",
    "bowel_signal_url": "https://www.fda.gov/drugs/fda-adverse-event-monitoring-system-aems/april-june-2025-new-safety-information-or-potential-signals-serious-risks-identified-fda-adverse",
    "verified_date": "2026-08-01",
    "dataset_version\r": "1.0\r"
  },
  {
    "cohort_id": "FDA-AEMS-2023-Q3-GLP1-08",
    "product_name": "Saxenda",
    "active_ingredient": "liraglutide",
    "aspiration_fda_outcome": "Label updated October–November 2024",
    "alopecia_fda_outcome": "Alopecia added December 2024–May 2025",
    "bowel_exact_phrase_present": "True",
    "bowel_label_result": "Exact phrase present",
    "si_b_2026_action": "Removed February 25, 2026 (S-025)",
    "current_label_source_type": "DailyMed label",
    "current_label_url": "https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=3946d389-0926-4f77-a708-0acb8153b143",
    "si_b_source_url": "https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2026/206321Orig1s025ltr.pdf",
    "cohort_definition_url": "https://www.fda.gov/drugs/fda-adverse-event-monitoring-system-aems/july-september-2023-potential-signals-serious-risksnew-safety-information-identified-fda-adverse",
    "bowel_signal_url": "https://www.fda.gov/drugs/fda-adverse-event-monitoring-system-aems/april-june-2025-new-safety-information-or-potential-signals-serious-risks-identified-fda-adverse",
    "verified_date": "2026-08-01",
    "dataset_version\r": "1.0\r"
  },
  {
    "cohort_id": "FDA-AEMS-2023-Q3-GLP1-09",
    "product_name": "Soliqua 100/33",
    "active_ingredient": "insulin glargine and lixisenatide",
    "aspiration_fda_outcome": "Label updated October–November 2024",
    "alopecia_fda_outcome": "Alopecia added December 2024–May 2025",
    "bowel_exact_phrase_present": "True",
    "bowel_label_result": "Exact phrase present",
    "si_b_2026_action": "Not part of 2026 removal request",
    "current_label_source_type": "DailyMed label",
    "current_label_url": "https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=4bba538b-cf7c-4310-ae8f-cb711ed21bcc",
    "si_b_source_url": "",
    "cohort_definition_url": "https://www.fda.gov/drugs/fda-adverse-event-monitoring-system-aems/july-september-2023-potential-signals-serious-risksnew-safety-information-identified-fda-adverse",
    "bowel_signal_url": "https://www.fda.gov/drugs/fda-adverse-event-monitoring-system-aems/april-june-2025-new-safety-information-or-potential-signals-serious-risks-identified-fda-adverse",
    "verified_date": "2026-08-01",
    "dataset_version\r": "1.0\r"
  },
  {
    "cohort_id": "FDA-AEMS-2023-Q3-GLP1-10",
    "product_name": "Trulicity",
    "active_ingredient": "dulaglutide",
    "aspiration_fda_outcome": "Label updated October–November 2024",
    "alopecia_fda_outcome": "Alopecia added December 2024–May 2025",
    "bowel_exact_phrase_present": "True",
    "bowel_label_result": "Exact phrase present",
    "si_b_2026_action": "Not part of 2026 removal request",
    "current_label_source_type": "DailyMed label",
    "current_label_url": "https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=463050bd-2b1c-40f5-b3c3-0a04bb433309",
    "si_b_source_url": "",
    "cohort_definition_url": "https://www.fda.gov/drugs/fda-adverse-event-monitoring-system-aems/july-september-2023-potential-signals-serious-risksnew-safety-information-identified-fda-adverse",
    "bowel_signal_url": "https://www.fda.gov/drugs/fda-adverse-event-monitoring-system-aems/april-june-2025-new-safety-information-or-potential-signals-serious-risks-identified-fda-adverse",
    "verified_date": "2026-08-01",
    "dataset_version\r": "1.0\r"
  },
  {
    "cohort_id": "FDA-AEMS-2023-Q3-GLP1-11",
    "product_name": "Victoza",
    "active_ingredient": "liraglutide",
    "aspiration_fda_outcome": "Label updated October–November 2024",
    "alopecia_fda_outcome": "Alopecia added December 2024–May 2025",
    "bowel_exact_phrase_present": "True",
    "bowel_label_result": "Exact phrase present",
    "si_b_2026_action": "Not part of 2026 removal request",
    "current_label_source_type": "DailyMed label",
    "current_label_url": "https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=5a9ef4ea-c76a-4d34-a604-27c5b505f5a4",
    "si_b_source_url": "",
    "cohort_definition_url": "https://www.fda.gov/drugs/fda-adverse-event-monitoring-system-aems/july-september-2023-potential-signals-serious-risksnew-safety-information-identified-fda-adverse",
    "bowel_signal_url": "https://www.fda.gov/drugs/fda-adverse-event-monitoring-system-aems/april-june-2025-new-safety-information-or-potential-signals-serious-risks-identified-fda-adverse",
    "verified_date": "2026-08-01",
    "dataset_version\r": "1.0\r"
  },
  {
    "cohort_id": "FDA-AEMS-2023-Q3-GLP1-12",
    "product_name": "Wegovy",
    "active_ingredient": "semaglutide",
    "aspiration_fda_outcome": "Label updated October–November 2024",
    "alopecia_fda_outcome": "Existing labeling adequate; no further action at that time",
    "bowel_exact_phrase_present": "True",
    "bowel_label_result": "Exact phrase present",
    "si_b_2026_action": "Removed February 25, 2026 (S-033/S-004)",
    "current_label_source_type": "DailyMed label",
    "current_label_url": "https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=ee06186f-2aa3-4990-a760-757579d8f77b&type=display",
    "si_b_source_url": "https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2026/215256Orig1s033%2C218316Orig1s004ltr.pdf",
    "cohort_definition_url": "https://www.fda.gov/drugs/fda-adverse-event-monitoring-system-aems/july-september-2023-potential-signals-serious-risksnew-safety-information-identified-fda-adverse",
    "bowel_signal_url": "https://www.fda.gov/drugs/fda-adverse-event-monitoring-system-aems/april-june-2025-new-safety-information-or-potential-signals-serious-risks-identified-fda-adverse",
    "verified_date": "2026-08-01",
    "dataset_version\r": "1.0\r"
  },
  {
    "cohort_id": "FDA-AEMS-2023-Q3-GLP1-13",
    "product_name": "Xultophy 100/3.6",
    "active_ingredient": "insulin degludec and liraglutide",
    "aspiration_fda_outcome": "Label updated October–November 2024",
    "alopecia_fda_outcome": "Alopecia added December 2024–May 2025",
    "bowel_exact_phrase_present": "True",
    "bowel_label_result": "Exact phrase present",
    "si_b_2026_action": "Not part of 2026 removal request",
    "current_label_source_type": "DailyMed label",
    "current_label_url": "https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=21335fe4-d395-4501-ac2a-2f20d7520da9&type=display",
    "si_b_source_url": "",
    "cohort_definition_url": "https://www.fda.gov/drugs/fda-adverse-event-monitoring-system-aems/july-september-2023-potential-signals-serious-risksnew-safety-information-identified-fda-adverse",
    "bowel_signal_url": "https://www.fda.gov/drugs/fda-adverse-event-monitoring-system-aems/april-june-2025-new-safety-information-or-potential-signals-serious-risks-identified-fda-adverse",
    "verified_date": "2026-08-01",
    "dataset_version\r": "1.0\r"
  },
  {
    "cohort_id": "FDA-AEMS-2023-Q3-GLP1-14",
    "product_name": "Zepbound",
    "active_ingredient": "tirzepatide",
    "aspiration_fda_outcome": "Label updated October–November 2024",
    "alopecia_fda_outcome": "Existing labeling adequate; no further action at that time",
    "bowel_exact_phrase_present": "True",
    "bowel_label_result": "Exact phrase present",
    "si_b_2026_action": "Removed February 25, 2026 (S-042)",
    "current_label_source_type": "DailyMed label",
    "current_label_url": "https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=487cd7e7-434c-4925-99fa-aa80b1cc776b",
    "si_b_source_url": "https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2026/217806Orig1s042ltr.pdf",
    "cohort_definition_url": "https://www.fda.gov/drugs/fda-adverse-event-monitoring-system-aems/july-september-2023-potential-signals-serious-risksnew-safety-information-identified-fda-adverse",
    "bowel_signal_url": "https://www.fda.gov/drugs/fda-adverse-event-monitoring-system-aems/april-june-2025-new-safety-information-or-potential-signals-serious-risks-identified-fda-adverse",
    "verified_date": "2026-08-01",
    "dataset_version\r": "1.0"
  }
]